Skip to main content

Finland s Chip-Man Raises 1.4M Euro to Develop Cell-Analysis Platform

NEW YORK, March 21 (GenomeWeb News) - Chip-Man Technologies, a Tampere, Finland-based developer of cellular analysis technology, said today that it has secured €1.4 million in first-round financing.

 

The company will use the funding, provided by Aura Capital and Finnish Industry Investment, to further develop its Cell-IQ cell analysis platform.

 

The company's Cell-IQ system monitors morphological and physiological changes in cell lines, primary cells, co-cultures, and monolayer tissue models in real time.

 

Chip-Man said that the market for automated cell analysis tools in pharmaceutical and medical research is estimated at around $500 million and is growing at 30 percent annually.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.